BofA analyst Travis Steed raised the firm’s price target on Boston Scientific (BSX) to $120 from $115 and keeps a Buy rating on the shares. The company’s Q2 results continued to show strong upside with 17% organic growth, 28% watchman growth, and 94% EP growth, the analyst tells investors in a research note. The firm added that Q2 margins were also good excluding the transcatheter aortic valve replacement write-off, and noted that Boston Scientific is starting to see synergies between EP and Watchman post-concomitant expansion.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Morning Movers: Fiserv sinks following second quarter results
- Boston Scientific raises FY25 EPS view to $2.95-$2.99 from $2.87-$2.94
- Boston Scientific reports Q2 adjusted EPS 75c, consensus 73c
- Boston Scientific sees Q3 adjusted EPS 70c-72c, consensus 70c
- Notable companies reporting before tomorrow’s open